Report Adverse Event or Product Quality Complaint    US Site     Global Site

AZmedical Information Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
    • Oncology Pipeline Tool
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an Medical Information Request
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • ISA 2026

International Symposium on Amyloidosis (ISA 2026)

November 15 – 18, 2026

  1. All
  2. ATTR Amyloidosis
  3. Wainua (eplontersen)

HTML

Efficacy and safety of eplontersen in patients with hereditary versus wild-type transthyretin cardiomyopathy (ATTR-CM): Results from the CARDIO-TTRansform study

HTML

Reliability and Validity of the Transthyretin Amyloidosis - Quality of Life Questionnaire (ATTR-QOL) Symptom Scales

HTML

Sex-related differences in participants with transthyretin amyloid cardiomyopathy (ATTR-CM) receiving eplontersen: results from the CARDIO-TTRansform study

HTML

An interactive dashboard using real-world study data to inform clinical practice and improve quality of care: ConducTToR

HTML

Cardiac insights and early findings from MaesTTRo: Exploring Transthyretin Amyloidosis Through a Prospective Multi-National Real-World Study

HTML

Neurological Characteristics of ATTR-PN and Mixed Phenotype Across Age and Sex in a Multi-National Study

HTML

Patient characteristics, clinical variables, and quality-of-life in patients with transthyretin amyloidosis: a MaesTTRo interim analysis

HTML

Sex-associated differences post-diagnosis of wild-type transthyretin amyloidosis cardiomyopathy - an OverTTuRe analysis

HTML

Efficacy and safety of eplontersen in patients with hereditary versus wild-type transthyretin cardiomyopathy (ATTR-CM): Results from the CARDIO-TTRansform study

HTML

Reliability and Validity of the Transthyretin Amyloidosis - Quality of Life Questionnaire (ATTR-QOL) Symptom Scales

HTML

Sex-related differences in participants with transthyretin amyloid cardiomyopathy (ATTR-CM) receiving eplontersen: results from the CARDIO-TTRansform study

HTML

An interactive dashboard using real-world study data to inform clinical practice and improve quality of care: ConducTToR

HTML

Cardiac insights and early findings from MaesTTRo: Exploring Transthyretin Amyloidosis Through a Prospective Multi-National Real-World Study

HTML

Patient characteristics, clinical variables, and quality-of-life in patients with transthyretin amyloidosis: a MaesTTRo interim analysis

HTML

Sex-associated differences post-diagnosis of wild-type transthyretin amyloidosis cardiomyopathy - an OverTTuRe analysis

HTML

Neurological Characteristics of ATTR-PN and Mixed Phenotype Across Age and Sex in a Multi-National Study

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 5/26

Contact Us

About Us

AstraZeneca-US.com

Other Countries

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States